Tag: death

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.).

Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

Primo Brands Reports Second Quarter 2025 Results

Revises full year 2025 Net Sales, Adjusted EBITDA, and Adjusted Free Cash Flow guidanceReaffirms cost synergy capture targets of $200 million in 2025; $300...

Carriage Services Announces Second Quarter 2025 Results, Strategic Acquisitions, and Raises Full-Year 2025 Outlook

Conference call on Thursday, August 7, 2025 at 8:00 a.m. Central Time

Conference call on Thursday, August 7, 2025 at 8:00 a.m. Central Time

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

NSC and Safety On The Edge Announce Strategic Co-location in Baltimore

WASHINGTON, Aug. 6, 2025 /PRNewswire/ -- The National Safety Council and Safety On The Edge Global Forum are proud to announce a groundbreaking partnership that...

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation

Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing...

Breakthrough T1D, formerly JDRF, Leads Multi-Stakeholder Summit in Udaipur, India Highlighting Urgent Need for Early Diagnosis, Access to Care, and Stigma Reduction for Type...

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Breakthrough T1D International, the leading global type 1 diabetes (T1D) research and advocacy organization, in partnership with Friends of...

New National Survey from Automatic Trap Company Shows 88% of Travelers Will Give a 1-Star Rating If a Rodent is Seen at a Vacation...

Airbnb, rental, hotel, and motel owners take note – a new national survey revealed that 88% of people will not hesitate to give a...

Legionnaires’ Disease Lawyers Retained to Investigate Central Harlem Legionnaires’ Disease Outbreak

HARLEM, N.Y., Aug. 5, 2025 /PRNewswire/ -- Legionnaires' disease lawyer Jory Lange and prominent Manhattan attorney Scott Harford have been retained to investigate an...

International Sensation “The Story of Marceau Miller” Gets English-Language Release with Blackstone Publishing

Sold in twelve countries, "The Story of Marceau Miller," a buzzy literary thriller that has captivated publishing audiences worldwide, is Blackstone Publishing’s inaugural translated novel.

Sold in twelve countries, "The Story of Marceau Miller," a buzzy literary thriller that has captivated publishing audiences worldwide, is Blackstone Publishing’s inaugural translated novel.

Services PMI® at 50.1%; July 2025 Services ISM® Report On Business®

Business Activity Index at 52.6%; New Orders Index at 50.3%; Employment Index at 46.4%; Supplier Deliveries Index at 51% TEMPE, Ariz., Aug. 5, 2025 /PRNewswire/ --...

Intas Pharmaceuticals Launches HETRONIFLY™ (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer

AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage...

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsDeath

MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale